Drug Profile
Research programme: antibody-based cancer therapeutics - Affimed Therapeutics
Alternative Names: AFM 12; AFM 18; AFM 20; AFM 21; AFM 22; AFM 24+; AFM24_I; AFM24_T; anti CD19 x anti CD16; anti CD33 X anti CD3; anti-EGFRvIII/CD16A Tand AB; anti-EGFRvIII/CD3 TandAb; anti-EpCAM TandAb; Antibody-based non-Hodgkin's lymphoma therapeutics - Affimed; MHC-peptide complex antibody - Affimed; Trispecific AbsLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Affimed Therapeutics
- Developer Affimed Therapeutics; Amphivena Therapeutics
- Class Bispecific antibodies; Immunotherapies; Monoclonal antibodies; Trispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; B-cell maturation antigen modulators; CD19 antigen modulators; CD200 antigen modulators; CD3 antigen modulators; CD33 antigen modulators; Epidermal growth factor receptor antagonists; Epithelial cell adhesion molecule inhibitors; FCGR3A protein modulators; Immunomodulators; Major histocompatibility complex inhibitors; Matrix metalloproteinase 1 inhibitors; Natural killer cell stimulants; Phagocyte stimulants; T lymphocyte stimulants; T-lymphocyte differentiation antigen agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; Cancer; Colorectal cancer; Head and neck cancer; Lung cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in Germany (Parenteral)
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in Germany (Parenteral)
- 28 May 2021 No recent reports of development identified for preclinical development in Colorectal-cancer in Germany (Parenteral)